Minerva Neurosciences (NASDAQ:NERV) Stock Crosses Below 200 Day Moving Average – Here’s Why

Minerva Neurosciences, Inc. (NASDAQ:NERV) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.80 and traded as low as $2.44. Minerva Neurosciences shares last traded at $2.46, with a volume of 42,326 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on NERV shares. StockNews.com started coverage on shares of Minerva Neurosciences in a research note on Friday. They set a “sell” rating on the stock. HC Wainwright dropped their price target on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th.

Minerva Neurosciences Stock Up 0.4 %

The firm’s 50 day simple moving average is $2.68 and its 200 day simple moving average is $2.80.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Equities research analysts forecast that Minerva Neurosciences, Inc. will post -2.26 EPS for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.